Rockville-based Supernus Pharmaceuticals, headquartered at 9715 Key West Ave., has announced plans to merge with Indivior Pharmaceuticals in a deal that will create a larger company focused on developing and selling medications that treat conditions affecting the brain and nervous system, including neurological disorders, mental health conditions and addiction.
The all-stock merger is expected to close during the fourth quarter of 2026, pending approval from shareholders and regulators. The combined company will operate under the Supernus name and remain headquartered in Rockville, with current Supernus President and CEO Jack Khattar continuing to lead the business.
Together, the companies will have a portfolio of 11 medications and are expected to generate approximately $2.2 billion in annual revenue. Company officials say the merger will also save an estimated $125 million per year by combining operations and reducing costs.
Supernus said the larger company will be in a stronger financial position to invest in new medicines, expand its existing products and pursue future acquisitions. “This merger brings together two complementary organizations with a shared vision of improving the lives of people living with central nervous system diseases,” Khattar said. “With our combined commercial expertise and enhanced capabilities, we are well positioned to drive significant, durable growth across our diversified portfolio of medicines.”
The combined company’s board will include representatives from both businesses, with Supernus appointing four directors, including Khattar, and Indivior appointing four directors. Tony Kingsley, a member of Indivior’s board, will serve as board chair. Under the terms of the agreement, Indivior shareholders will own approximately 56.5% of the combined company, while Supernus shareholders will own about 43.5%.
Supernus said maintaining its headquarters in Rockville reinforces Montgomery County’s position as one of the region’s leading life sciences hubs. The merger is expected to become final later this year, assuming it receives the required shareholder and regulatory approvals.
